AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$LQDA

Boyle Dana sold $68K of LQDA

Boyle Dana (Chief Accounting Officer) sold 1,581 shares of Liquidia Corp (LQDA) at $43.19 on 2026-10-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Boyle Dana
Published Oct 28, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The disclosed sale is the first public report of this transaction, offering new data for investors.

02

Market read

A modest insider sell with limited immediate market impact.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 2/10Novelty 2/10Timing: today

Background

SEC Form 4 filings provide primary disclosure of insider transactions.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Form 4 disclosed Chief Accounting Officer Boyle Dana sold 1,581 shares for $68,283, a new insider sale.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

The transaction size is modest ($68k) and the insider is a senior officer, but the sale is disclosed for the first time.

Market effects

Sector

Minimal impact on the biotech sector; typical insider sales are routine.

Regional

No regional effect.

Global

Negligible.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a negative signal.

Key entities

  • Company
    Liquidia Corp

    Biotech firm listed on Nasdaq under ticker LQDA.

  • Person
    Boyle Dana

    Chief Accounting Officer of Liquidia Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

zacks.com
$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

investing.com
$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

finance.yahoo.com
$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.

finance.yahoo.com